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hemorrhage, bronchial- or mainstem stenosis are relatively 
unusual and may develop beyond 4 years after treatment.  
Estimation of the probability to develop RP is important for 
patients with inoperable lung cancer. Studies of the risk of 
RP have used various dosimetric parameters like the Mean 
Lung Dose (MLD) or V20. To increase the sensitivity to predict 
RP, dosimetric and non-dosimetric factors can be combined. 
Palma et al (ref 1) performed a meta-analysis of both 
dosimetric and non-dosimetric factors based on individual 
patients treated with concurrent chemoradiation. The factors 
predicting RP were type of chemotherapy 
(carboplatin/paclitaxel vs cisplatin/etoposide or other 
chemotherapy), age, MLD and V20. Pre-existing radiological 
interstitial lung disease (ILD) findings were analyzed in a 
recent Japanese study of 157 patients and correlated with 
the incidence of RP after stereotactic body radiation therapy 
(SBRT) for stage I NSCLC (ref 2). Multivariate analysis 
identified ILD as risk factor for ≥ Gr2 RP, as well as the 
irradiated lung volume. 
Recall radiation pneumonitis describes a rare reaction in 
previously irradiated lung tissue after application of 
triggering agents. Recall RP has been associated with 
multiple drugs such as taxanes, gemcitabine, vinca alkaloids, 
adriamycin and epirubicin. Tyrosine kinase inhibitors 
(erlotinib, cetuximab, sunitinib) have also been associated 
with recall RP and increased risk of severe RP following 
palliative or definitive radiation therapy. Some researchers 
have found a significant correlation between pulmonary 
toxicity and pre- and post radiation therapy pulmonary 
function tests. However, reduction in e.g. diffusion capacity 
varies widely between the grades of RP, making it less useful 
in routine clinical practice.  
To improve the quality of lung toxicity reporting 
investigations of Patient Reported Outcome (PRO) tools are 
being developed. In literature discrepancies between 
patients and clinicians reported toxicity as well as low 
correlation with CTCAE scoring are reported. Generally 
clinicians tend to underreport the incidence and severity of 
symptoms. In a recently published analysis of lung cancer 
patients treated with radiotherapy/chemoradiation 
agreement ranged from slight to substantial (ref 3). These 
differences underline the significance of the introduction of 
PROs in clinical trials. 
Summary: Dosimetric and clinical factors help us to estimate 
the incidence and severity of radiation induced pulmonary 
toxicity in clinical practice. In addition to these factors PROs 
tools on toxicity should be integrated in daily routine and in 
clinical trials to facilitate the doctors and patients decisions 
in the near future. 
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Radiotherapy (RT) plays a major role in the management of 
lung cancer as most patients are not surgical candidates due 
to stage, fitness and comorbidities. In the last decade we 
have witnessed tremendous changes in the role of radiation 
for the radical treatment of lung cancer as a result of the 
optimisation of chemo-radiotherapy combinations and 
technological advances. 
The technology available for RT planning, delivery and 
verification of lung cancer treatment is evolving at a fast 
pace. Unfortunately the evidence to demonstrate the benefit 
of such technology in terms of toxicity, local control, survival 
or quality of life is limited.  
Despite advances in the field of advanced RT techniques, 
local control with current RT doses delivered with standard 
3D conformal RT is poor with local progression-free survival 
rates of about 30 %, even with concurrent CTRT. It is now 
well accepted that that improved local control in lung cancer 
can lead to improvement in survival [Aupérin A. J Clin Oncol 
2010].   The following strategies can be combined to improve 
outcome in lung cancer include: 
•   Use of  Intensity-modulated radiotherapy 
IMRT is a  technique that adds fluence modulation to beam 
shaping, which improves radiotherapy dose conformity 
around the tumour and spares surrounding normal structures. 
Treatment with IMRT is becoming more widely available for 
the treatment of lung cancer, despite the paucity of high 
level evidence supporting the routine use of this more 
resource intense and complex technique [Chan. JTO 2014]. It 
allows the treatment of patients with large volume disease, 
close to critical organs at risk with curative doses. 
·          Dose escalation 
A clear radiation dose–response relationship exist in locally 
advanced NSCLC [Martel. Lung Cancer 1999]. The relationship 
between local control and BED is further suggested by data 
from SABR studies. The encouraging results of phase 1 and 2 
dose studies conducted in the 1990s formed the basis for the 
RTOG 0617 study [Bradley. ASCO 2013]. In that 2 x 2 factorial 
design study, patients with stage III NSCLC were randomized 
to receive high dose (74 Gy in 37 fractions) or standard dose 
(60 Gy in 30 fractions) RT concurrently with weekly 
paclitaxel/carboplatin with or without cetuximab. 
Disappointingly, there was a significant increase in the risk of 
death in the high-dose arms (median survival, 19.5 months vs 
28.7 months; p=0.0007), and a 37% increase in the risk of 
local failure in the high-dose arms (hazard ratio, 1.37; 
p=0.0319). There is therefore no role for dose escalation in 
stage III NSCLC using conventional dose fractionation 
·          Acceleration  
Hyperfractionated and/or accelerated fractionating 
schedules have demonstrated superior survival compared to 
conventional fractionation at the expense of greater 
oesophageal toxicity [Mauguen JCO 2012] 
·          Dose redistribution based on functional imaging 
Targeted dose escalation to tumour volumes resistant to 
treatment or at increased risk for recurrence is under 
evaluation [NCT01024829 and NCT01507428] 
•           Individualisation  of the dose (concept of isotoxic RT) 
The recognition of cancer heterogeneity has driven us away 
from the ‘one size fits all’ approach and has allowed tailoring 
of treatment to individualised patient-tumour characteristics. 
Isotoxic radiotherapy is a novel concept of personalised 
radiotherapy treatment allowing the individualised 
administration of radiotherapy dose based on predefined 
normal tissue constraints. 
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Purpose/Objective: Loco-regional recurrences remain 
frequent in locally advanced non-small cell lung cancer 
(NSCLC) patients and are predominantly located in the area 
of the primary tumor. Improved tumor control might be 
accomplished by dose-escalation and dose-redistribution. The 
PET-boost trial (NCT01024829) is an ongoing randomized 
phase II trial investigating individualized accelerated dose-
escalation to the entire primary tumor (arm A) or 
redistributed to regions of high FGD-uptake within the 
primary tumor (arm B). We present a planned interim 
analysis of the toxicity of 63 randomized patients. 
Materials and Methods: Patients with NSCLC stage IB-III, a 
primary tumor (PT) ≥4 cm and a SUVmax ≥5 are treated with 
chemo-radiation or radiotherapy alone. Treatment plans are 
designed using a pre-treatment FDG-PET-CT-scan with similar 
dose limits to OAR as in conventionally treated patients. If 
normal tissue constraints allow dose-escalation using an 
integrated boost ≥72 Gy in 24 fractions to the PT and with 
equal mean lung dose for both study arms, a patient is 
randomized to arm A or arm B. Involved lymph nodes are 
treated to a fractionation dose of 66 Gy in 24 fractions. 
Toxicity is scored according to the CTCAEv3.0 criteria. 
Endpoints are local progression-free survival at 1 year, 
toxicity, overall survival and quality of life. 
Results: From April 2010 to March 2014, 32 patients were 
randomized to arm A and 31 patients to arm B. Forty-eight 
patients received concurrent chemo-radiotherapy. Median 
follow-up was 25.5 months. The mean PT volume in arm A 
was 123.4cc and in arm B 181.5cc. Mean prescribed dose to 
the planning target volume of the primary tumor was 3.3 Gy 
(range 3.0-4.0 Gy) in arm A and 3.9 Gy (range 3.2-5.4 Gy) in 
arm B. Grade ≥3 dysphagia and dyspnea during treatment 
occurred in 7 and 2 patients (11 and 3%). Grade ≥3 
esophagitis and pneumonitis after treatment was seen in 11 
and 6 patients (17.5% and 9.5%). Hematologic toxicity grade 
≥3 was observed in 5%. Four out of 63 patients (6.3%) died 
due to pulmonary hemorrhage.  
Conclusions: This interim toxicity analysis of the randomized 
phase II PET-boost trial shows that dose-escalation is feasible 
in 63 randomized patients. The toxicity observed during and 
after treatment shows no excess or unexpected toxicity.  
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Purpose/Objective: The prognostic value of standardized 
uptake value (SUV) distribution of the fluorine-18 labeled 
glucose analog (FDG), has been widely studied for the 
primary tumor in non-small cell lung cancer (NSCLC) patients. 
However, nodal stage determines treatment choice and is 
related to disease progression and its capability to 
metastasize. We hypothesize that more PET-related 
prognostic information can be extracted from affected 
hilar/mediastinal lymph nodes than in the primary tumor. 
Therefore, we analyzed the SUV distribution and volume of 
the primary tumor and affected lymph nodes prior to 
radiotherapy. 
Materials and Methods: A cohort of 352 stages I-III NSCLC 
patients referred for primary (chemo)radiotherapy was 
included. The gross tumor volume of the primary tumor 
(GTVprim) and the metastatic lymph nodes (GTVln) had been 
manually delineated for treatment planning purposes. The 
nodal positive subset of patients (272) was selected for a 
comparison analysis based on volume and SUV descriptors 
(maximum, mean and peak), as derived from both the 
primary tumor and the affected lymph nodes, of the pre-
radiotherapy PET scan. The prognostic value of each of the 
metrics to overall survival (OS), recorded from start of 
radiotherapy until last day of follow-up or death by any 
cause, was evaluated through a Cox Proportional Hazards 
regression. 
Results: We first compared the distribution of volume and 
common SUV descriptors of the primary tumor for N=0 (80) 
and N+ (272) NSCLC patients. The GTVprim of patients without 
affected lymph nodes was metabolically more active (SUVmax 
= 13 ± 6.3; p<0.01, and SUVpeak = 10.3 ± 5.1; p=0.02) and 
larger (volume = 127.3 ± 235.4; p < 0.01) than the GTVprim of 
patients with affected lymph nodes. 
Mean ranks difference (Wilcoxon test) of volume and SUV 
descriptors of both GTVprim and GTVln was conducted for the 
nodal positive subset of patients, for which statistically 
significant (p<0.001) differences between metrics derived 
from the two structures could be shown (see table).  
The prognostic value of each of the metrics to OS was 
evaluated through a Cox Proportional Hazards regression. 
None of the metrics derived from the primary tumor were 
associated with OS in our cohort. However, the same metrics, 
extracted from the involved lymph nodes, were prognostic 
for survival with mean SUV showing the strongest correlation 
with OS (HR=1.14, p < 0.01). Also, tumor load, defined as 
GTVprim + GTVln showed a statistically significant correlation 
with OS. Currently, a multivariate analysis and collection of 
an external dataset for validation is ongoing. 
